DermTech (Warrants) (DMTKW)

[db7]

'was' holding up well, someone just market sold 55k and dumped it from .60 to .20

[db7]

https://investors.dermtech.com/news-releases/news-release-details/dermtech-inc-reports-fourth-quarter-and-full-year-2019-financial

[db7]

https://finance.yahoo.com/news/large-registry-study-demonstrates-clinicians-130000568.html

[greens12]

Warrants getting hot...love the action today. When they go to 5.00 wake me up...


DMTKW

[db7]

BEAUTIFUL day: DMTK $16, DMTKW $0.58

[db7]

Today's presentation: http://wsw.com/webcast/svbleerink34/dmtk/

[db7]

two 250k trades @ $0.35 today

[Jwit56]

Wow! News is looking up!

[db7]

DermTech to Present at Upcoming Investor Conferences

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that John Dobak, M.D., Chief Executive Officer of the Company, is scheduled to present at the following upcoming investor conferences:
• The 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 2:30 p.m. Eastern Time at the Lotte New York Palace hotel in New York.
• Cowen’s 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. Eastern Time at the Boston Marriott Copley Place hotel in Boston.

About DermTech:

DermTech is a leader in a new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the performance, patient benefits and cost-effectiveness of DermTech’s products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.



View source version on businesswire.com: https://www.businesswire.com/news/home/20200211006081/en/

Company Contact:
Sarah Dion
VP Marketing
[e-mail]
[phone]

Investors:
Westwicke, an ICR company
Caroline Corner, PhD
[e-mail]
[phone]

[db7]

1,120,756 traded @ .35 today

[db7]

New Presentation: https://www.sec.gov/Archives/edgar/data/1651944/000156459020002551/dmtk-ex991_6.htm

[greens12]

I left a message For Kevin Sun a week ago and still have not heard back. Will try again.

DMTK

[db7]

https://www.businesswire.com/news/home/20200108005028/en/

[db7]

hi greens, i'm not sure; you could contact Kevin Sun at Dermtech and ask(?)

being listed would be great as the warrants would get a lot more action IMO

'but' the nature of what they represent, if DMTK gets over $23 they 'will' respond IMO

g/l!!

[greens12]

400 round lot holders ? will dmtk management get it listed back on Nasdaq once there are 400 ? with all recent activity is it possible ? TIA db7.

DMTKW

[db7]

"The Panel also determined to delist the Company’s warrants previously trading on The Nasdaq Capital Market under the ticker symbol “DMTKW” (the “Public Warrants”) due to the Company’s failure to demonstrate compliance with Nasdaq Listing Rule 5515(a)(4), which requires the Company to have a minimum of 400 round lot holders of its publicly traded warrants. Accordingly, the Company’s Public Warrants were suspended from The Nasdaq Capital Market effective at the open of trading on October 18, 2019. On the same day, the Public Warrants became available for quotation under the symbol “DMTKW” on the Pink Market operated by OTC Markets Group Inc"

[greens12]

Why were the warrants delisted on Nasdaq ?

DMTKW

[db7]

HOD-> DMTK: $15.48, DMTKW: $0.38

[db7]

'if' DMTK pulls back, I'd imagine you might be able to get some .20's but we'll see what she's going to do next week.

I'm letting my friends and family in DMTK common know to make sure they're in it prior to the close every Wednesday as we're expecting the medicare news on a Thursday. (this applying to the one(s) trying to swing in and out instead of just sitting tight)

g/l and have a great weekend!

[greens12]

I picked up some Warrants today @.35...will add more next week.


DMTKW

[db7]

from .10ish to .34 and just the beginning IMHO... still only 3 board followers here-

[db7]

HOD-> DMTK: $9.44, DMTKW: $0.30

[db7]

g/l!

[greens12]

Thanks for the info db7, i will be buying a few Warrants in the near future ...the payout is huge. GL

DMTKW

[db7]

Hi Greens12, these 'were' trading really nicely out of the gate until they were delisted from Nasdaq. Although the volume/attention on them isn't as great as when Nasdaq-listed their attraction/investment potential doesn't change IMO. I 'personally' chose to change my entire position in Dermtech from a mixture of common/warrants to strictly warrants based on the 'possible' amplified leverage they bring. 'I believe' DMTK will trade above $30 (and possibly) much higher by time the warrants expire in 2024.

Common vs warrant examples (from my original entry points for simplicity):

my averages were/are:
DMTK $5.55
DMTKW $0.1136

'if' DMTK hits $30 'before' the 2024 DMTKW expiration:
DMTK $5.55 to $30.00
DMTKW $.1136 to $1.75 (likely higher due to premium too)


'if' DMTK hits $40 'before' the 2024 DMTKW expiration:
DMTK $5.55 to $40.00
DMTKW $.1136 to $4.25 (likely higher due to premium too)


'if' DMTK hits $50 'before' the 2024 DMTKW expiration:
DMTK $5.55 to $50.00
DMTKW $.1136 to $6.75 (likely higher due to premium too)



of course the flipside to my love story above is if DMTK never breaches $23 before 2024:
DMTK $5.55 to $23.00 (nice gain!)
DMTKW $.1136 to $0 (oops!!!!!!!!!!)




Good Luck!!!!!!!!!!!!

[greens12]

There is never much volume here any thought as to why ? I read that you do not have any more commons ,only Warrants , how come ? does it make a difference that the Warrants are on the OTC and not Nasdaq? Is it only because they did not have 400 round lot holders or were there other reasons ?


DMTKW

[db7]

https://dermtech.com/wp-content/uploads/DermTech-IR-Deck-10-24-19-Final.pdf

[db7]

DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association
Print
Alert
DermTech (NASDAQ:DMTK)
Intraday Stock Chart
Today : Monday 28 October 2019

Click Here for more DermTech Charts.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the AMA has issued a Proprietary Laboratory Analyses (PLA) Common Procedural Terminology (CPT®) Code for the DermTech Pigmented Lesion Assay. This PLA code was published online with an effective date of July 1, 2019 and is included in the CPT 2020 publication. Medicare rate setting for this proprietary laboratory assay code is currently in process and is expected to be finalized effective for dates of service on or after January 1, 2020.

Burkhard Jansen, M.D., DermTech’s Chief Medical Officer commented, “The receipt of this CPT code is another step toward broadening our contracting and reimbursement success for the Pigmented Lesion Assay.”

DermTech’s Pigmented Lesion Assay uses RT-PCR to measure the gene expression of two genes, LINC00516 (long-intergenic non-coding RNA 00516) and PRAME (preferentially expressed antigen in melanoma) and identifies the malignant changes of melanoma on the genomic level.

About DermTech:

DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the pricing and reimbursement of DermTech’s Pigmented Lesion Assay. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the company; (2) the inability to maintain the listing of the company’s securities on Nasdaq; (3) the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition, the ability of the company to grow and manage growth profitably and retain its key employees; (4) costs related to or resulting from the business combination; (5) changes in applicable laws or regulations; (6) the demand for the company’s services together with the possibility that the company may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties included in (x) the “Risk Factors” sections of the Registration Statement on Form S-4 filed with the SEC by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.



View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005279/en/

Sarah Dion
VP Marketing
[e-mail]
[phone]

[db7]

DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its common stock will continue trading on The Nasdaq Capital Market under the symbol “DMTK.” On October 16, 2019, the Nasdaq Hearings Panel (the “Panel”) notified DermTech that it has granted the Company’s request for continued listing of its common stock on The Nasdaq Capital Market because the Company meets all of the requirements for initial listing.

The Panel also determined to delist the Company’s warrants previously trading on The Nasdaq Capital Market under the ticker symbol “DMTKW” (the “Public Warrants”) due to the Company’s failure to demonstrate compliance with Nasdaq Listing Rule 5515(a)(4), which requires the Company to have a minimum of 400 round lot holders of its publicly traded warrants. Accordingly, the Company’s Public Warrants were suspended from The Nasdaq Capital Market effective at the open of trading on October 18, 2019. On the same day, the Public Warrants became available for quotation under the symbol “DMTKW” on the Pink Market operated by OTC Markets Group Inc. Quotes can be found at www.otcmarkets.com.

About DermTech:

DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the Company’s ability to maintain its listing on The Nasdaq Capital Market. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the company; (2) the inability to maintain the listing of the company’s securities on Nasdaq; (3) the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition, the ability of the company to grow and manage growth profitably and retain its key employees; (4) costs related to or resulting from the business combination; (5) changes in applicable laws or regulations; (6) the demand for the company’s services together with the possibility that the company may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties included in (x) the “Risk Factors” sections of the Registration Statement on Form S-4 filed with the SEC by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.



View source version on businesswire.com: https://www.businesswire.com/news/home/20191018005566/en/

Kevin Sun
[e-mail]
[phone]

[db7]

DMTKW now on OTC daily list; warrants delisted from Nasdaq

[db7]

TallTrader, thanks for confirming! I had both DMTK and DMTKW but have sold the common and now have a large position in the warrants.

Company has a game-changing product IMO and these warrants give it a long time to play out.

good luck!

[TallTrader]

Confirmed with CFO...

The original terms were two warrants to buy 1 share @ 11.50, but after the reverse split…

Is it now four warrants to buy 1 share at $23 with an expiration date 8/29/2024 (five years).

But, you may want to confirm yourself.

I OWN SHARES IN DMTKW PURCHASED IN THE OPEN MARKET.